Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

y 31, 2008, the Company had cash and cash equivalents totaling $23,263,000, compared to $11,379,000 at July 31, 2007. The increase in cash and cash equivalents is the result of a private placement completed on December 19, 2007, when the Company issued 10,040,000 common shares for gross proceeds totaling $16,867,200. The total number of common shares issued as of January 31, 2008, was 46,375,335, compared to 36,335,335 in the same period last year. At January 31, 2008, the Company's working capital was $23,016,000, compared to $11,468,000 at July 31, 2007. After taking into consideration the Company's anticipated revenue, planned research and development expenditures and the assumption that there will not be unanticipated expenses, the Company expects that its current working capital will be sufficient to finance operations beyond the 2010 fiscal year.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing or delaying one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Calif., Dec. 12 Codexis, Inc., a leading,developer ... directors have been named to the company,s Board ... Vice President of Innovation and,Chemicals Technology, Shell Global ... Dennis Wolf, Executive Vice President and CFO, MySQL, ...
... PLYMOUTH MEETING, Pa., Dec. 12 Genaera,Corporation (Nasdaq: ... Executive Officer of Genaera, is scheduled to present at ... part of an,RBC Capital Markets, panel discussion of diabetes ... and will take place in,New York on Thursday, December ...
... First Time on 50 mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive ... of Wyeth (NYSE: WYE ), announces that data from,two ... inhibitor (SNRI), showed,that adult patients who received a 50 mg/day ...
Cached Biology Technology:Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... Change , suggests that if current trends continue ... targets for total greenhouse gas (GHG) emissions in 2050. ... about the food we choose and its environmental impact. A ... of a number of actions that need to be taken ... food for all. , As populations rise and global ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... into a calcium-sensing enzyme already known to play a ... researchers showed that the enzyme, calmodulin kinase II (CaM ... disease called Timothy syndrome and that inhibiting the enzyme ... a new cellular model, could help with developing treatments ...
... Climate change can have significant impacts on high-elevation lakes ... them, according to U.S. Forest Service and University of ... issue of the journal " Herpetological Conservation and Biology ... shallow lakes drying up in summer and predation by ...
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
Cached Biology News:Rare disease provides clues about enzyme role in arrhythmias 2Rare disease provides clues about enzyme role in arrhythmias 3Climate change effects on imperiled Sierra frog examined 2UQ research targets West Nile virus and dengue fever 2
NORMAL DONOR DONKEY SERUM...
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Biology Products: